首页 | 本学科首页   官方微博 | 高级检索  
检索        

脑血疏口服液联合神经节苷脂治疗急性脑出血的疗效观察
引用本文:刘乃彦,张化民.脑血疏口服液联合神经节苷脂治疗急性脑出血的疗效观察[J].现代药物与临床,2016,31(12):1901-1904.
作者姓名:刘乃彦  张化民
作者单位:连云港市赣榆区人民医院神经内科,江苏连云港,222100
摘    要:目的观察脑血疏口服液联合神经节苷脂治疗急性脑出血的临床疗效。方法选取2012年1月—2015年12月在连云港市赣榆区人民医院接受急性脑出血治疗的患者82例,随机分成对照组和治疗组,每组各41例。对照组患者根据出血情况静脉滴注单唾液酸四己糖神经节苷脂钠注射液,50~80 m L加入到250 m L生理盐水中,1次/d,两周之后根据患者情况减量,维持20~40 m L/d。治疗组患者在对照组的基础上口服脑血疏口服液,10 m L/次,3次/d。两组患者均连续治疗1个月。比较两组患者临床疗效、脑血肿和脑水肿量减少量、神经功能缺损程度(NIHSS)评分、改良Barthel指数(BI)评分以及日常生活能力(ADL)评分变化。结果治疗后,对照组和治疗组总有效率分别为78.05%和92.68%,两组总有效率比较差异具有统计学意义(P0.05)。治疗后,两组患者脑血肿和脑水肿减少量均比治疗前明显减少(P0.05);且治疗后治疗组脑血肿和脑水肿减少量比对照组的更明显(P0.05)。治疗后,两组患者NIHSS评分比治疗前明显降低,BI和ADL评分比治疗前明显升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组患者上述指标评分改善程度优于对照组,两组比较差异具有统计学意义(P0.05)。结论脑血疏口服液联合神经节苷脂治疗急性脑出血能有效减少患者脑血肿和脑水肿量,降低神经功能缺损程度,提高改良BI,增强日常生活能力,具有一定的临床推广应用价值。

关 键 词:脑血疏口服液  单唾液酸四己糖神经节苷脂钠注射液  急性脑出血  脑血肿  脑水肿
收稿时间:2016/6/21 0:00:00

Clinical observation of Naoxueshu Oral Liquid combined with ganglion glycoside in treatment of acute cerebral hemorrhage
LIU Nai-yan and ZHANG Hua-min.Clinical observation of Naoxueshu Oral Liquid combined with ganglion glycoside in treatment of acute cerebral hemorrhage[J].Drugs & Clinic,2016,31(12):1901-1904.
Authors:LIU Nai-yan and ZHANG Hua-min
Institution:Department of Neurology, Ganyu District People''s Hospital of Lianyungang City, Lianyungang 222100, China;Department of Neurology, Ganyu District People''s Hospital of Lianyungang City, Lianyungang 222100, China
Abstract:Objective To observe the clinical effect of Naoxueshu Oral Liquid combined with ganglion glycoside in treatment of acute cerebral hemorrhage. Methods Patients (82 cases) with acute cerebral hemorrhage in Ganyu District People''s Hospital of Lianyungang City from January 2012 to December 2015 were randomly divided into the control and treatment groups, and each group had 41 cases. The patients in the control group were iv administered with Monosialotetrahexosylganglioside Sodium Injection, 50-80 mL added into normal saline 250 mL, once daily, and the dosage was reduced according to patient''s condition after 2 weeks, which maintained at 20-40 mL/d. The patients in the treatment group were po administered with Naoxueshu Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy, the volume change of brain hematoma and cerebral edema, NIHSS scores, BI scores, and ADL scores in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment group were 78.05% and 92.68%, respectively, and there were differences between two groups (P<0.05). After treatment, the volume change of brain hematoma and cerebral edema in two groups were significantly decreased (P<0.05). And the volume change of brain hematoma and cerebral edema in the treatment group were decreased more obviously than those in the control group (P<0.05). After treatment, NIHSS score in two groups was decreased, but BI and ADL scores were increased, and the difference was statistically significant in the same group (P<0.05). And these observation indexes in the treatment group were better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Naoxueshu Oral Liquid combined with ganglion glycoside has effect in treatment of acute cerebral hemorrhage, can effectively reduce the volume of brain hematoma and cerebral edema and NIHSS, also improve BI and the ability of daily life, which has a certain clinical application value.
Keywords:Naoxueshu Oral Liquid  Monosialotetrahexosylganglioside Sodium Injection  acute cerebral hemorrhage  brain hematoma
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号